Compare Iovance Biotherapeutics Inc. Common Stock (IOVA) vs Kyndryl Holdings Inc (KD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Iovance Biotherapeutics Inc. Common Stock vs Kyndryl Holdings Inc — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.63 (market cap $6.04B), while Kyndryl Holdings Inc trades at $11.75 (market cap $2.59B). The key difference: Iovance Biotherapeutics Inc. Common Stock is far larger — about 2.3× Kyndryl Holdings Inc's market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Kyndryl Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Kyndryl Holdings Inc for 36 Days on average.
| IOVA | KD | |
|---|---|---|
Market Cap | $6.04B | $2.59B |
Volume | 14,805,993 | 5,354,348 |
Sector | Health | Technology |
52-Week High | $14.82 | $29.76 |
52-Week Low | $1.81 | $10.59 |
Typical Hold Time | 0 Days | 36 Days |
Enterprise Value | $5.97B | $5.41B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kyndryl (KD) trades at $11.75, up 2.62% with bearish technical signals but improving fundamentals. The company reported positive net income of $252M in 2025 after years of losses, with revenue stabilizing around $15B. Recent news highlights AI initiatives including a new Dallas innovation lab and healthcare IT acquisition. Analyst consensus is mixed with 71% hold ratings but a $14.67 price target suggesting 25% upside potential.
KD shows fundamental improvement with profitability returning, though earnings misses and competitive pressures remain risks. The stock trades at reasonable valuations (P/S 0.18x) but faces execution challenges in its AI transformation. Institutional interest is building with recent purchases, but technical weakness suggests near-term consolidation likely before sustained upward movement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →About Kyndryl Holdings Inc
Kyndryl Holdings Inc is a technology services and infrastructure services provider company. It provides advisory, implementation, and managed services across a range of technology domains to help customers manage and modernize enterprise IT environments in support of their business and transformation objectives.
Read more on KD →
